Historical Valuation
Structure Therapeutics Inc (GPCR) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.00 is considered Undervalued compared with the five-year average of -34.32. The fair price of Structure Therapeutics Inc (GPCR) is between +Inf to +Inf according to relative valuation methord. Compared to the current price of 83.58 USD , Structure Therapeutics Inc is Undervalued By Fair.
Relative Value
Fair Zone
+Inf-+Inf
Current Price：83.58
Fair
Undervalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Structure Therapeutics Inc (GPCR) has a current Price-to-Book (P/B) ratio of 5.37. Compared to its 3-year average P/B ratio of 3.68 , the current P/B ratio is approximately 46.03% higher. Relative to its 5-year average P/B ratio of 3.68, the current P/B ratio is about 46.03% higher. Structure Therapeutics Inc (GPCR) has a Forward Free Cash Flow (FCF) yield of approximately -4.17%. Compared to its 3-year average FCF yield of -6.68%, the current FCF yield is approximately -37.56% lower. Relative to its 5-year average FCF yield of -6.68% , the current FCF yield is about -37.56% lower.
Competitors Valuation Multiple
AI Analysis
The average P/S ratio for GPCR competitors is 233.31, providing a benchmark for relative valuation. Structure Therapeutics Inc Corp (GPCR.O) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
AI Analysis
1Y
3Y
5Y
Market capitalization of GPCR increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of GPCR in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is GPCR currently overvalued or undervalued?
Structure Therapeutics Inc (GPCR) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.00 is considered Undervalued compared with the five-year average of -34.32. The fair price of Structure Therapeutics Inc (GPCR) is between +Inf to +Inf according to relative valuation methord. Compared to the current price of 83.58 USD , Structure Therapeutics Inc is Undervalued By Fair .
What is Structure Therapeutics Inc (GPCR) fair value?
GPCR's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Structure Therapeutics Inc (GPCR) is between +Inf to +Inf according to relative valuation methord.
How does GPCR's valuation metrics compare to the industry average?
The average P/S ratio for GPCR's competitors is 233.31, providing a benchmark for relative valuation. Structure Therapeutics Inc Corp (GPCR) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for Structure Therapeutics Inc (GPCR) as of Jan 15 2026?
As of Jan 15 2026, Structure Therapeutics Inc (GPCR) has a P/B ratio of 5.37. This indicates that the market values GPCR at 5.37 times its book value.
What is the current FCF Yield for Structure Therapeutics Inc (GPCR) as of Jan 15 2026?
As of Jan 15 2026, Structure Therapeutics Inc (GPCR) has a FCF Yield of -4.17%. This means that for every dollar of Structure Therapeutics Inc’s market capitalization, the company generates -4.17 cents in free cash flow.
What is the current Forward P/E ratio for Structure Therapeutics Inc (GPCR) as of Jan 15 2026?
As of Jan 15 2026, Structure Therapeutics Inc (GPCR) has a Forward P/E ratio of -43.34. This means the market is willing to pay $-43.34 for every dollar of Structure Therapeutics Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Structure Therapeutics Inc (GPCR) as of Jan 15 2026?
As of Jan 15 2026, Structure Therapeutics Inc (GPCR) has a Forward P/S ratio of 0.00. This means the market is valuing GPCR at $0.00 for every dollar of expected revenue over the next 12 months.